Adjuvant selection for influenza and RSV prefusion subunit vaccines

Simple item page
dc.contributor.authorIsaacs, A.
dc.contributor.authorLi, Z.
dc.contributor.authorCheung, S.T.M.
dc.contributor.authorWijesundara, D.K.
dc.contributor.authorMcMillan, C.L.D.
dc.contributor.authorModhiran, N.
dc.contributor.authorYoung, P.R.
dc.contributor.authorRanasinghe, C.
dc.contributor.authorWatterson, D.
dc.contributor.authorChappell, K.J.
dc.date.issued2021
dc.description.abstractSubunit vaccines exhibit favorable safety and immunogenicity profiles and can be designed to mimic native antigen structures. However, pairing with an appropriate adjuvant is imperative in order to elicit effective humoral and cellular immune responses. In this study, we aimed to determine an optimal adjuvant pairing with the prefusion form of influenza haemagglutinin (HA) or respiratory syncytial virus (RSV) fusion (F) subunit vaccines in BALB/c mice in order to inform future subunit vaccine adjuvant selection. We tested a panel of adjuvants, including aluminum hydroxide (alhydrogel), QS21, Addavax, Addavax with QS21 (AdQS21), and Army Liposome Formulation 55 with monophosphoryl lipid A and QS21 (ALF55). We found that all adjuvants elicited robust humoral responses in comparison to placebo, with the induction of potent neutralizing antibodies observed in all adjuvanted groups against influenza and in AdQS21, alhydrogel, and ALF55 against RSV. Upon HA vaccination, we observed that none of the adjuvants were able to significantly increase the frequency of CD4<sup>+</sup> and CD8<sup>+</sup> IFN-γ<sup>+</sup> cells when compared to unadjuvanted antigen. The varying responses to antigens with each adjuvant highlights that those adjuvants most suited for pairing purposes can vary depending on the antigen used and/or the desired immune response. We therefore suggest that an adjuvant trial for different subunit vaccines in development would likely be necessary in preclinical studies.
dc.description.statementofresponsibilityAriel Isaacs, Zheyi Li, Stacey T. M. Cheung, Danushka K. Wijesundara, Christopher L. D. McMillan, Naphak Modhiran ...et al.
dc.identifier.citationVaccines, 2021; 9(2):1-14
dc.identifier.doi10.3390/vaccines9020071
dc.identifier.issn2076-393X
dc.identifier.issn2076-393X
dc.identifier.orcidWijesundara, D.K. [0000-0002-0740-8362]
dc.identifier.urihttp://hdl.handle.net/2440/129967
dc.language.isoen
dc.publisherMDPI
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/APP1125107
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/APP1144025
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
dc.source.urihttps://doi.org/10.3390/vaccines9020071
dc.subjectRSV
dc.subjectadjuvant
dc.subjectinfluenza
dc.subjectmicrobiology
dc.subjectvaccine
dc.subjectvirology
dc.titleAdjuvant selection for influenza and RSV prefusion subunit vaccines
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_129967.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Microbiology and Immunology publications